48th week of 2010 patent applcation highlights part 41 |
Patent application number | Title | Published |
20100303798 | Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions. | 2010-12-02 |
20100303799 | Treatment of Conditions Related to Shock - Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques. | 2010-12-02 |
20100303800 | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIA - A method for treating ischemia that would benefit from angiogenesis is disclosed. The method comprises administering to a subject in need thereof a composition comprising: a) a fragment of human thrombomodulin in a therapeutically effective amount; and b) a pharmaceutically acceptable carrier; wherein the fragment comprises the amino acids Ala242 to Ser515 of SEQ ID NO: 2. | 2010-12-02 |
20100303801 | Host cell specific binding molecules capable of neutralizing viruses and uses thereof - The present invention provides human binding molecules specifically binding to a host cell protein and having virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of viral infections. | 2010-12-02 |
20100303802 | ANTIBODY DIRECTED TO G PROTEIN COUPLED RECEPTORS (GPCR) - The present invention provides an antibody directed to an epitope of a G-protein coupled receptor, wherein the antibody binds to the extracellular N-terminal region of the receptor and the binding of the antibody to the G-protein coupled receptor induces receptor internalization in cells. | 2010-12-02 |
20100303803 | CATENATE FOR IMMUNOSTIMULATION - The invention relates to a multimeric, non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a production method therefor, and to a vaccine containing said multimeric, non-coding nucleic acid molecule. Said multimeric, non-coding nucleic acid molecules can be non-coding nucleic acid molecules that consist of at least two of said molecules (dimer) or assemblies of several non-coding nucleic acid molecules. | 2010-12-02 |
20100303804 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL - The present invention relates to a polymerization-curable composition for the preparation of biodegradable, biocompatible, cross-linked polymers on the basis of polyvinyl alcohol comprising: 5 to 100% by weight of (a) vinyl ester monomer(s) of one of the general formulas (I) to (III): | 2010-12-02 |
20100303805 | IDENTIFICATION OF SMALL MOLECULES RECOGNIZED BY ANTIBODIES IN SUBJECTS WITH NEURODEGENERATIVE DISEASES - The present invention provides for the identification of individuals having neurodegenerative diseases (ND). Peptoids recognized by Parkinson's Disease- and Alzheimer's Disease-specific antibodies are identified, allowing one to diagnose or predict ND in subjects. | 2010-12-02 |
20100303806 | Avian derivedantibodies - The invention encompasses among other things antibodies including cytotoxic antibodies such as anti-CD20 having avian N-linked glycosylation patterns obtained from egg white of eggs laid by transgenic avians. | 2010-12-02 |
20100303807 | METHODS FOR THE TREATMENT OF IL-1BETA RELATED DISEASES - Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 2010-12-02 |
20100303808 | HUMANIZED ANTI-CD20 ANTIBODIES AND METHODS OF USE - Humanized anti-CD20 antibodies are provided that may be used for the treatment of diseases and conditions associated with CD20-expressing cells. Also provided are nucleic acids enoding such antibodies, methods of making such antibodies, and compositions comprising such antibodies. | 2010-12-02 |
20100303809 | METHODS FOR THE DETECTION AND QUANTITATION OF PTEN - The present disclosure provides methods for determining if PTEN is elevated or reduced in one or more tumor cells relative to one or more normal cells in the same biological sample by obtaining a biological sample comprising one or more tumor cells and one or more normal cells; assaying the biological sample for expression of PTEN; quantitating an amount of PTEN expression in the one or more tumor cells and an amount of PTEN expression in the one or more normal cells; comparing the amount of PTEN expression in the tumor cells to the amount of PTEN expression in the normal cells; and determining that PTEN is elevated in the tumor cells where the amount of expression of PTEN is greater in the tumor cells as compared to the normal cells or determining that PTEN is reduced in the tumor cells where the amount of expression of PTEN is less in the tumor cells than in the normal cells. Such methods may be used to predict whether a patient will be responsive to treatment with one or more receptor tyrosine kinase inhibitors and/or may be used to select subjects for inclusion/exclusion in a clinical trial. | 2010-12-02 |
20100303810 | METHOD FOR TREATING LUPUS - A method of treating lupus in a subject eligible for treatment is provided involving administering an effective amount of an antibody that binds to a B-cell surface marker to the subject to provide an initial exposure and a subsequent exposure to the antibody within certain dosing regimens and an article of manufacture therefor. | 2010-12-02 |
20100303811 | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity. - The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated. | 2010-12-02 |
20100303812 | NEUTRALIZING MONOCLONAL ANTIBODY AGAINST HUMAN DLL4 - The present invention provides a binding protein capable of binding to DLL4 as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4. | 2010-12-02 |
20100303813 | BIOMARKERS FOR PREDICTING ANTI-TNF RESPONSIVENESS OR NON-RESPONSIVENESS - The present disclosure provides biomarkers that are predictive a subject's responsiveness or non-responsiveness to an anti-TNF therapy. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities (e.g., an anti-TNF therapy or a non-anti-TNF therapy) for a subject suffering from a disease such as an immune disorder. | 2010-12-02 |
20100303814 | Antibodies Against a Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof - The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Heterogeneous Ribonucleoprotein G (HnRNPG). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens of variant HnRNPG, and uses thereof. | 2010-12-02 |
20100303815 | METHOD OF TREATING ANEMIA BY ADMINISTERING IL 1ra - The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist. | 2010-12-02 |
20100303816 | ANTIBODIES AGAINST HUMAN MELANOMA-ASSOCIATED CHONDROITIN SULPHATE PROTEOGLYCAN (MCSP) - The present invention provides isolated antibodies (e.g., humanized or human antibodies) that bind to the membrane-proximal domain (MP) of human Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP), and are capable of mediating cytolysis of a cell expressing MCSP in the presence of human effector cells or complement. Methods of using such antibodies to induce cytolysis (e.g., ADCC or CDCC) of cells expressing MP-MCSP are also provided. | 2010-12-02 |
20100303817 | ANTIBODIES TO TREAT CANCER - Compositions and methods for the treatment of cancer, particularly melanoma, myeloma, small cell lung cancer, thymic lymphoma, T-cell lymphoma, B-cell lymphoma, osteosarcoma, and acute T-cell leukemia, are disclosed. Illustrative compositions include one or more anti-ganglioside antibodies and polynucleotides that encode such anti-ganglioside antibodies. These antibodies may be for example, hamster antibodies, chimeric human/hamster antibodies, or humanized antibodies. The disclosed compositions are useful, for example, in the treatment of cancer and can be used to induce apoptosis in a cancer cell. | 2010-12-02 |
20100303818 | Dendritic cell receptor - The invention provides isolated human DEC-205, its extracellular domain and functionally equivalent fragments thereof. Also provided are polynucleotides encoding same and vectors which include such polynucleotides. Further provided are methods of recombinantly producing human DEC-205, an extracellular domain thereof or a functionally equivalent fragment, and ligands that bind to human DEC-205 or a fragment thereof. Also provided are constructs for use in prophylaxis or therapy comprising such a ligand, human DEC-205 or an extracellular domain thereof coupled to a toxin or to an antigen capable of inducing a protective immune response in a patient. | 2010-12-02 |
20100303819 | DCL-1 AND USES THEREOF - The present invention relates generally to a novel lectin and to derivatives, homologues, analogues, chemical equivalents and mimetics thereof and, more particularly, to a novel type I C-type lectin, herein referred to as “DCL-1”. In particular, the present invention relates to the use of DCL-1 in therapeutic, prophylactic and diagnostic applications. | 2010-12-02 |
20100303820 | METHODS OF TREATMENT USING IL-17E ANTAGONISTS - Novel IL-17 like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing IL-17 like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with IL-17 like polypeptides, agonists, or antagonists thereof. | 2010-12-02 |
20100303821 | IMMUNOGLOBULINS - The present invention relates to antigen binding proteins to human IL-13, including anti-IL-13 antibodies and anti-IL-3/anti-IL-4 mAbdAbs, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as asthma or IPF. | 2010-12-02 |
20100303822 | Polypeptides from non-typeable haemophilus influenzae - Polypeptides comprising non-typeable | 2010-12-02 |
20100303823 | HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) - Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 2010-12-02 |
20100303824 | SIGNALING INTERMEDIATES IN AN IN VITRO MODEL OF ALZHEIMER'S DISEASE - The invention provides a novel human protein, FISH adaptor protein, involved in amyloid β-protein-mediated cell death. Also provided are methods for modulating amyloid β-protein-mediated cell death using agents that interfere with the activity of FISH adaptor protein. | 2010-12-02 |
20100303825 | ANTI-ESTROGEN AND IMMUNE MODULATOR COMBINATIONS FOR TREATING BREAST CANCER - Compositions for treating cancers of mucosal tissues including breast, prostate, ovary, colon are disclosed which include various combinations of new or conventional anti-estrogen compounds, aromatase inhibitors, immune modulators, immune inhibitors, immune inhibitor mimicking compounds and steroid or thyroid hormones. Methods of predicting susceptibility of a cancer of mucosal origin to treatment with a composition containing an immune inhibitor or an immune inhibitor mimicking compound are also disclosed. Preferred methods include identifying in a specimen of cancer cells the presence of a Poly-Ig (Fc) receptor or Poly-Ig-like (Fc) receptor capable of binding to an immune inhibitor or an immune inhibitor mimicking compound and of mediating immune inhibition of cancer cell growth. | 2010-12-02 |
20100303826 | Use of ADCC-Optimized antibodies for treating weak patients - The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism. | 2010-12-02 |
20100303827 | Protein Formulation - The present invention provides stable lyophilized formulations of bispecific antibodies or fragments thereof. | 2010-12-02 |
20100303828 | Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity - The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases. | 2010-12-02 |
20100303829 | HIV VPR-SPECIFIC T CELL RECEPTORS - The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQL (SEQ ID NO: 1)). | 2010-12-02 |
20100303830 | PREVENTION AND TREATMENT OF OTITIS MEDIA USING IgA ENRICHED MILK - This invention relates to a composition suitable for use in the prevention or treatment of otitis media comprising IgA derived from mature bovine milk and having specificity for at least one of | 2010-12-02 |
20100303831 | Methods For The Treatment Of An Infectious Bacterial Disease With An Anti-Lactone Or Lactone Derived Signal Molecules Antibody - The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant. | 2010-12-02 |
20100303832 | GENES AND POLYMORPHISMS ASSOCIATED WITH AMD - The invention relates to genes, gene polymorphisms, and genetic profiles associated with an elevated or a reduced risk of alternative complement cascade deregulation disease such as AMD. The invention provides methods and reagents for determination of risk, diagnosis and treatment of such diseases. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of a patient which facilitate assessment of risk for developing such diseases. | 2010-12-02 |
20100303833 | Method for Identifying a MHC Class H-Dependent Tumor Associated T Helper Cell Antigen - The present invention is a method for identifying MHC class II-dependent disease-associated antigens. The instant method involves expressing a library of disease-derived proteins in lytic bacteriophage for subsequent presentation by antigen presenting cells to T helper cells. Disease-associated antigens are provided as are the use of such antigens in vaccines for inducing an immune response and preventing or treating disease. Moreover, the present invention provides antibodies, which specifically bind to MHC class II-dependent disease-associated antigens or epitope peptides thereof, and their diagnostic and therapeutic use. | 2010-12-02 |
20100303834 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 2010-12-02 |
20100303835 | PEPTOID LIGANDS FOR ISOLATION AND TREATMENT OF AUTOIMMUNE T-CELLS - The present invention provides for the identification of autoreactive T cell populations from individuals having autoimmune diseases, such as multiple sclerosis and EAE. Peptoids recognized by autoreactive T cells can be used to identify various types of autoimmune disease, and can also be used to target therapies against such populations. | 2010-12-02 |
20100303836 | TREATMENT OF HYPERPROLIFERATIVE DISEASE WITH SUPERANTIGENS IN COMBINATION WITH ANOTHER ANTICANCER AGENT - The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal. | 2010-12-02 |
20100303837 | CARBOHYDRATE SPECIFIC CELLULAR IMMUNITY INDUCING MICROORGANISMS AND FRACTIONS THEREOF - The present invention relates to the field of prevention and treatment of disorders associated with the occurrence of certain carbohydrate epitopes. The present invention relates to the prevention and treatment of carbohydrate epitope positive tumors. The invention relates to formulations and methods for the induction of an effective carbohydrate specific cellular immune response. | 2010-12-02 |
20100303838 | VECTORS FOR MULTIPLE GENE EXPRESSION - The present invention provides a vector for expressing at least a first and a second nucleic acid molecules which exhibit a percentage of homology of approximately 80% or greater than 80% over a portion of 40 or more continuous nucleotides and wherein said first nucleic acid molecule and/or said second nucleic acid molecule is modified so as to reduce said percentage of homology to less than 75%. The present invention also relates to substantially isolated nucleic acid molecules comprising a nucleotide sequence as defined in any of SEQ ID NO: 9-15 and 66-69. It also provides a host cell and a pharmaceutical composition comprising such a nucleic acid molecule or vector as well as their use for therapeutic or preventive purposes. | 2010-12-02 |
20100303839 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER USING ONCOLYTIC RSV ACTIVITY - The present invention relates generally to methods and compositions employing the oncolytic activity of respiratory syncytial virus (RSV) to treat cancer and other neoplastic disorders. | 2010-12-02 |
20100303840 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM - The present invention relates to the use of creatine compounds including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer's disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group. | 2010-12-02 |
20100303841 | ADJUVANT - The subject invention provides new adjuvant therapy. | 2010-12-02 |
20100303842 | PEPTIDE ANALOGUES - Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed. | 2010-12-02 |
20100303843 | RECOMBINANT ALLERGEN WITH REDUCED lgE BINDING BUT UNDIMINISHED T-CELL ANTIGENICITY - The present invention relates generally to reagents useful in the immunotherapeutic or immunoprophylactic treatment of allergic diseases. More particularly, the present invention provides modified allergens exhibiting reduced IgE interactivity including reduced IgE production-stimulatory activity, while retaining T-cell antigenicity, which are useful in the immunomodulation of type I allergic disease conditions. The present invention further contemplates a method of immunomodulation of allergic diseases such as type I allergic disease conditions by the administration of modified allergens exhibiting reduced IgE interactivity while retaining T-cell antigenicity. | 2010-12-02 |
20100303844 | MODIFICATION OF INTRINSICALLY DISORDERED SEQUENCES FOR THE PREPARATION OF VACCINES - The intrinsically disordered sequences—or “intrinsically disorded sequences” or IDSeq—proteins should be flexible to ensure a controlled interaction between proteins. In the development of the diseases, IDSeq are modified and polymerized. The invention describes the method of preparation of the drugs against cancers, the degenerative diseases and the infectious illness, by the induction of an immune reaction against IDSeq modified in a covalent way (IDSeqC) and polymerized (pIDSeqC), and leading to a new network of protein signaling, named here “misfoldome”, causing the diseases. The invention describes the preparation of vaccines by the use of polymers of IDSeqC. Peptides of the pIDSeqC are prepared in vitro, and introduced into a living organism to induce an immunological response, which eliminates the “misfoldome” and cures the diseases. The method is employed for the preparation of active or passive vaccines. The technology is adapted to detect, prevent or cure the diseases associated with ageing such as the degenerative diseases, cancers, and infections. | 2010-12-02 |
20100303845 | NOVEL GENE EXPRESSED IN PROSTATE CANCER - A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer. | 2010-12-02 |
20100303846 | Immunostimulatory Nucleic Acid Packaged Particles for the Treatment of Hypersensitivity - The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy. | 2010-12-02 |
20100303847 | COMPOSITIONS OF TOLL-LIKE RECEPTOR AGONISTS AND PAPILLOMAVIRUS ANTIGENS AND METHODS OF USE THEREOF - Compositions that include at least one protein that activates a Toll-like Receptor and includes at least a portion of at least one Toll-like Receptor agonist and at least a portion of at least one papillomavirus suppressor binding protein, papillomavirus transforming protein and papillomavirus capsid protein can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can further include an adjuvant and a carrier protein. | 2010-12-02 |
20100303848 | VACCINATION METHOD - The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to methods of effecting local and systemic immunization against HIV while protecting cells (e.g., mucosal dendritic and epithelial cells) from viral challenge. The invention further relates to compounds (e.g., nucleic acids encoding polypeptides that can elicit an immune response and/or protect cells against viral challenge) and compositions suitable for use in such methods. | 2010-12-02 |
20100303849 | Lipidated Vaccine against Dengue Virus Infection - Disclosed are immunogenic composition, fusion proteins, and related methods for inducing immune response to dengue virus infection. | 2010-12-02 |
20100303850 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE - This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise immunomodulatory agents and antigens that are differentially released from the synthetic nanocarriers. | 2010-12-02 |
20100303851 | IMMUNOSTIMULATION BY CHEMICALLY MODIFIED RNA - The present invention relates to an immunostimulating agent comprising at least one chemically modified RNA. The invention furthermore relates to a vaccine which comprises at least one antigen in combination with the immunostimulating agent. The immunostimulating agent according to the invention and the vaccine according to the invention are employed in particular against infectious diseases or cancer diseases. | 2010-12-02 |
20100303852 | CONJUGATION PROCESS FOR PNAG AND A CARRIER PROTEIN - The present application describes a process for conjugating a PNAG which is less than 40% N-acetylated to a carrier protein. | 2010-12-02 |
20100303853 | Novel Nacl Salt Substitute Agent, Use Thereof and Products Containing Same - The present invention relates to a novel NaCl salt substitute agent free of aromatic flour and comprising at least one 5′-nucleotide yeast extract, preferably containing at least 1% of 5′-nucleotides relative to the solids content of the yeast extract, and a mixture of low-sodium potassium and ammonium salts, and to the use thereof as a salting agent. It also relates to the use of 5′-nucleotide yeast extract, preferably containing at least 1% of 5′-nucleotides relative to the solids content of the yeast extract, for the off-flavour masking effects thereof and/or for enhancing the salty taste and/or for reducing the amount of low-sodium potassium and/or ammonium salts. | 2010-12-02 |
20100303854 | BOTANICAL ANTI-ACNE FORMULATIONS - Disclosed is a topical skin care composition and corresponding methods for their use comprising | 2010-12-02 |
20100303855 | METHOD OF REDUCING ADVERSE EFFECTS OF THERAPEUTIC AGENTS FOR DYSLIPIDEMIA - A substance preventing adverse actions of conventional fibrate-series drugs as therapeutic agents for the metabolic syndrome and dyslipidemia to enhance the therapeutic effects thereof comprises an extract from | 2010-12-02 |
20100303856 | INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA) - The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine. | 2010-12-02 |
20100303857 | DEVELOPMENT OF A PREVENTIVE VACCINE FOR FILOVIRUS INFECTION IN PRIMATES - The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus. | 2010-12-02 |
20100303858 | Chimeric HIV-1 Glycoproteins and Their Biological Applications - The invention relates to chimeric HIV-1 gp120 glycoproteins, wherein at least a part of gp120 variable region V1 and/or V2 is replaced by a CD4-derived sequence to obtain the exposition of CD4 induced epitopes or CD4i capable of inducing a specific humoral immune response. Application for the preparation of vaccinal and pharmaceutical composition. | 2010-12-02 |
20100303859 | VECTORS AND METHOD FOR GENETIC IMMUNIZATION - Improved DNA vaccine plasmids are disclosed that contain novel immunostimulatory RNA compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short RNA based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation. These vectors are utilized in immunization to elicit improved immune responses or therapy to induce type 1 interferon production. | 2010-12-02 |
20100303860 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF VACCINES AGAINST DENGUE VIRUS - Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4. | 2010-12-02 |
20100303861 | Live Attenuated Vaccine Strain for Prevention of Tularemia - The invention provides live attenuated avirulent strains of | 2010-12-02 |
20100303862 | INCAPACITATED WHOLE-CELL IMMUNOGENIC BACTERIAL COMPOSITIONS PRODUCED BY RECOMBINANT EXPRESSION - The present invention features incapacitated whole-cell bacterial immunogenic compositions and methods of their production, which compositions are useful to deliver antigens in a manner resembling the live infectious organism in terms of elicitation of a robust immune response, but with reduced risk or no risk of disease. The compositions of the invention are produced by rendering a bacterium bacteriostatic through expression of a recombinant promoter in the bacterial cell, which promoter can be operably linked to a polynucleotide encoding a recombinant gene product. In one embodiment, where the bacterium is a gram negative host, the recombinant gene product provides for reduced toxicity of LPS. In one embodiment, the gene product is a bacteriophage protein, such as endolysin, holin, or ndd. | 2010-12-02 |
20100303863 | RECOMBINANT EDWARDSIELLA BACTERIUM - The present invention encompasses a recombinant | 2010-12-02 |
20100303864 | CONSERVED AND SPECIFIC STREPTOCOCCAL GENOMES - The invention relates to polynucleotides which are conserved or specific to one or more species of | 2010-12-02 |
20100303865 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES - The present invention relates to the use of compounds of formula (I), wherein R | 2010-12-02 |
20100303866 | IMMUNOGENIC PEPTIDES AND THEIR USE IN IMMUNE DISORDERS - The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognised by CD4+ T cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides of the invention have been shown to be useful a medicine, more in particular for the prevention or treatment of immune disorders, more specifically of allergic disorders or autoimmune diseases. The present invention thus provides for the use of said peptides for the manufacture of a medicament for the prevention or treatment of an immune disorder and further provides for methods of treatment or preventing immune disorders by using said peptides. The present invention also provides for compositions comprising said peptides. | 2010-12-02 |
20100303867 | A COMPOSITION COMPRISING A NOTCH LIGAND AND AN ALLERGENB OR ALLERGEN BYSTANDER ANTIGEN - A method is provided for reducing an immune response to an allergen or antigenic determinant thereof in a mammal by administering a modulator of the Notch signalling pathway. | 2010-12-02 |
20100303868 | EX VIVO, FAST AND EFFICIENT PROCESS TO OBTAIN ACTIVATED ANTIGEN-PRESENTING CELLS THAT ARE USEFUL FOR THERAPIES AGAINST CANCER AND IMMUNE SYSTEM-RELATED DISEASES - The present invention relates to an ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases. At the same time, it is related to a cellular composition that contributes to stimulate the activated antigen-presenting cells to induce a specific immune response against tumors in patients with cancer or other pathologies involving immune responses. | 2010-12-02 |
20100303869 | Process for Producing Antimicrobial-Coated Superabsorbents - Superabsorbents having a coating of an antimicrobial agent are produced by a process that comprises contacting the superabsorbent with a solution comprising the anti-microbial agent and a polyol concurrently with or immediately after contacting it with the surface-crosslinking agent and prior to the curing step that completes surface crosslinking, and/or contacting the superabsorbent with a solution comprising the anti-microbial agent and polyalkylene glycol of a molecular mass between 200 and 5 000 g/mol after completion of surface crosslinking. | 2010-12-02 |
20100303870 | METHODS OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) USING CYSTEAMINE PRODUCTS - The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | 2010-12-02 |
20100303871 | COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE-MEDIATED INTRACELLULAR SIGNAL TRANSDUCTION - Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide compositions and methods suitable for modulation of at least one of cellular membrane potential and cellular membrane conductivity. Additional aspects provide compositions and methods suitable for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically altered solutions to impart electrochemical and/or conformational changes in membranous structures (e.g., membrane proteins, receptors and/or other components) including G-protein coupled receptors (GPCRs), G-proteins, and/or intracellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). | 2010-12-02 |
20100303872 | USE OF A POLYPHENOL-RICH PLANT EXTRACT AS ANTIOXIDANT IN COMBINATION WITH A HYDRATING OR HUMECTANT AGENT - A polyphenol-rich plant extract is used in combination with at least one hydrating or humectant agent, as cosmetic active agents in a cosmetic composition. The combination improves hydrating and antioxidant cosmetic care. | 2010-12-02 |
20100303873 | BIODEGRADABLE SINGLE-PHASE COHESIVE HYDROGELS - Biodegradable single-phase cohesive hydrogels useful, e.g., for the formulation of viscosupplementation compositions or compositions for filling wrinkles, contain a homogeneous blend of x polymers, which may be identical or different, crosslinked prior to the interpenetration thereof by mixing in the form of a single-phase hydrogel, wherein such crosslinked polymers are insoluble in water and miscible with one another, and x ranges from 2 to 5; in one embodiment, the hydrogels are such that the x polymers have identical or different degrees of crosslinking, at least one of the x polymers having a degree of crosslinking x1 and at least one of the x polymers having a degree of crosslinking x2, with x1 being greater than or equal to x2. | 2010-12-02 |
20100303874 | ANISOTROPIC SELF-ASSEMBLY OF NANOPARTICLES IN COMPOSITES - An anisotropic self assembled structure comprises isotropic grafted nanoparticles in a polymeric matrix, the self-assembled structure comprising (a) a one-dimensional string of the grafted nanoparticles within the matrix, the string having a width of one nanoparticle and a length of 1-10 nanoparticles, (b) a substantially two-dimensional sheet of the grafted nanoparticles within the matrix, the sheet having a length and a breadth of at least one micron respectively, wherein the sheet is about 2-5 nanoparticles in thickness, or (c) a plurality of three dimensionally interconnected structures where the width of each of the structures is 1-10 nanoparticles; wherein each grafted nanoparticle comprises a substantially spherical inorganic core nanoparticle and a polymeric brush structure grafted thereto. | 2010-12-02 |
20100303875 | BIOCIDAL GRANULE, IN PARTICULAR FOR MAKING ASPHALT SHINGLE - The invention relates to biocidal granules composed of a mineral core coated with at least one porous inorganic layer including at least one organic compound capable of limiting or preventing the growth of microorganisms, in particular of algae. | 2010-12-02 |
20100303876 | METHOD FOR PREPARING SILVER NANOPARTICLES - The invention relates to a method for preparing silver nanoparticles having a diameter lower than 80 nm, and dispersed in a polymer matrix in a concentration higher than 1 M, that comprises the following steps: i) mixing an organic silver salt and a polymer having an alcohol terminal function in a solvent containing at least one alcohol fraction; ii) agitating and heating the mixture obtained during the previous step; and iii) separating the polymer phase charged with silver nanoparticles. | 2010-12-02 |
20100303877 | Controlled Release Hydrogel Films - The present invention provides hydrogels and methods of making hydrogels with precisely controlled levels of chemical compositions by mixing one or more monomers in a plasma reactor; polymerizing the one or more monomers into a polymer; crosslinking the polymer to form a hydrogel; immersing the hydrogel in a first solution; and adsorbing one or more solute species from the solution, wherein the one or more solute species are released at controlled rates. | 2010-12-02 |
20100303878 | BIODEGRADABLE BIOACTIVE AGENT RELEASING MATRICES WITH PARTICULATES - The present invention is directed to biodegradable polymeric matrices for the controlled release of a hydrophilic bioactive agent. Generally, the biodegradable matrices include an aliphatic polyester copolymer and microparticulates that include the hydrophilic bioactive agent. In some embodiments, the matrix includes a second biodegradable polymer comprising hydrophilic and hydrophobic portions. Exemplary matrix forms are device coatings and medical implants. Matrices of the invention demonstrated high bioactive agent loading, were able to modulate release of the bioactive agent in a therapeutic manner, and also maintained high levels of activity for therapeutically useful large molecule bioactive agents, such as proteins. | 2010-12-02 |
20100303879 | SILANE-FUNCTIONALIZED HYDROPHOBIC a(1-4)GLUCOPYRANOSE POLYMERS AND POLYMERIC MATRICES FOR IMPLANTATION OR INJECTION - Silane-functionalized hydrophobic α(1→4)glucopyranose polymers and polymeric matrices are described. Biodegradable matrices can be formed from hydrophobic α(1→4)glucopyranose polymers with reactive pendent silyl ether groups. Reaction of the silyl ether groups provides improved matrix formation through bonding to a device surface of a device, polymer-polymer crosslinking, or both. Biodegradable matrices can be used for the preparation of implantable and injectable medical devices, including those that release a bioactive agent. | 2010-12-02 |
20100303880 | Tissue scaffolding comprising surface folds for tissue engineering - The invention is directed to solid gradient scaffolds, methods of producing the same, and therapeutic applications arising from their utilization. Specifically, the gradient scaffolding includes, inter-alia, surface folds of various configuration for increasing surface area to volume of the scaffold. | 2010-12-02 |
20100303881 | Therapeutic Electrospun Fiber Compositions - The instant invention provides electrospun fiber compositions comprising one or more polymers and one or more biologically active agents. In specific embodiments, the biologically active agents are nerve growth factors. In certain embodiments, the electrospun fiber compositions comprising one or more biologically active agents are on the surface of a film, or a tube. The tubes comprising the electrospun fiber compositions of the invention can be used, for example, as nerve guide conduits. | 2010-12-02 |
20100303882 | Medical Devices for Localized Drug Delivery - In certain embodiments, the invention relates to an implantable medical device that includes a body having an internal cavity. Receptor sites in the internal cavity may be adapted to repeatedly bind to, temporarily hold, and release an active agent. An opening may extend through the body and into the internal cavity to allow the active agent into and out of the internal cavity. This opening may be sized and shaped to prevent blood cells from entering the internal cavity through the opening while allowing the active agent to enter and/or exit the cavity via the opening. A polymeric structure may be located in the internal cavity. This polymeric structure may include artificial receptor site mimics for the active agent. | 2010-12-02 |
20100303883 | POLYMERIC DRUG DELIVERY SYSTEMS AND THERMOPLASTIC EXTRUSION PROCESSES FOR PRODUCING SUCH SYSTEMS - Implants are disclosed for delivery of therapeutic agents such as opioids and the manufacture and uses of such implants. | 2010-12-02 |
20100303884 | GROWTH FACTOR COMPLEXES AND MODULATION OF CELL MIGRATION AND GROWTH - Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, KGF, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer. | 2010-12-02 |
20100303885 | METHOD FOR PRODUCING AN IMPLANTABLE BONE COMPOSITION - Disclosed are methods for producing implantable bone compositions suitable for attaching stem cells thereto, characterized in that bone particles are contacted with an albumin comprising solution. Said bone particles can be mineralized and/or lyophilized bone particles of animal or human origin. Preferably the non-immunogenic albumin comprising solution is lyophilized onto said bone particles. The invention further concerns bone compositions suitable for use in graft implantation obtainable by said methods. | 2010-12-02 |
20100303886 | GRAFT MATERIALS AND METHODS FOR STAGED DELIVERY OF BIOACTIVE COMPONENTS - Described, in certain aspects of the invention, are multilaminate medical graft products, as well as methods for preparing and using the same. An illustrative multilaminate medical graft product of the invention comprises a first layer of remodelable extracellular matrix (ECM) material bonded to a second layer of remodelable ECM material, wherein the first material layer is enriched with a growth factor relative to the second material layer. Such a remodelable ECM material may be comprised of submucosa from a warm-blooded vertebrate, for example, porcine small intestinal submucosa (SIS). | 2010-12-02 |
20100303887 | DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells - The combination of pigment epithelium-derived factor (PEDF) and docosahexaenoic acid (DHA) has been discovered to act synergistically to enhance cell survival and decrease apoptosis in retinal pigment epithelial (RPE) cells. PEDF and DHA synergistically protected RPE cells by confronted with oxidative stress by blocking apoptotic cell death and increasing the synthesis of the important mediator neuroprotectin D 1. Administering a composition comprising PEDF and DHA will halt or slow down the initiation and progression of macular degeneration, retinitis pigmentosa and retinal degeneration. In addition, the topical application of the combination of PEDF and DHA was found to promote cornea nerve regeneration after refractive surgery, and thus this combination could be used to prevent the complications of refractive surgery and certain diseases, e.g., neurotrophic keratitis due to Herpes virus. | 2010-12-02 |
20100303888 | COMPOSITION FOR ENHANCING BONE FORMATION - Disclosed herein is a matrix for inducing or enhancing osteoclast differentiation. The matrix comprises a material having an osteoclastogenic agent associated therewith, the agent being releasable from the material in an amount which is sufficient to induce or enhance osteoclast differentiation. | 2010-12-02 |
20100303889 | Compositions and Methods for Promoting Patency of Vascular Grafts - Methods for increasing the patency of biodegradable, synthetic vascular grafts are provided. The methods include administering one or more cytokines and/or chemokines that promote outward tissue remodeling of the vascular grafts and vascular neotissue formation. The disclosed methods do not require cell seeding of the vascular grafts, thus avoiding many problems associated with cell seeding. Biodegradable, polymeric vascular grafts which provide controlled release of cytokines and/or chemokines at the site of vascular graft implantation are also provided. | 2010-12-02 |
20100303890 | COPOLYMERS SUITABLE FOR USE IN CORNEAL BANDAGES - Disclosed is a polymer having an affinity for corneal cells such that it can be used as a substrate for the growth of corneal cells, and so is suitable for use in a corneal bandage, especially in the form of a contact lens in which at least the cornea contacting surface is composed of the polymer. The substrate with an affinity for corneal cells is a copolymer comprising units -(A)- and -(B)- in which the units A are derived from aminoalkyl (alkyl)acrylates and the units B are derived from aryloxy, alkoxy or hydroxyalkyl (alkyl)acrylates, and (alkyl)acrylic acids. | 2010-12-02 |
20100303891 | SUPRAMACROMOLECULAR POLYMER COMPLEXES PROVIDING CONTROLLED NITRIC OXIDE RELEASE FOR HEALING WOUNDS - A bio-adhesive supramacromolecular complex of the general formula: | 2010-12-02 |
20100303892 | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ELONGATE HOLLOW BODIES - The invention relates to a transdermal therapeutic system for applying an active ingredient or several active ingredients to the skin. Elongate hollow bodies are incorporated into one of the layers of the TTS, said hollow bodies containing a filling medium or several filling mediums. The invention also relates to the production and use of said type of systems. | 2010-12-02 |
20100303893 | NOVEL COMPOUND FOR TREATMENT OF TUMOR - Specific modifying agent is coupled to an anti-tumor protein on a certain site. It conquers the disadvantages which include high antigenicity, short circulating half-life, nonuniform modified sites, inhomogeneous component, reduced activity and uncontrollable quality of the products prepared by non-specific modifying method. The anti-tumor protein coupled with specific modifying agent can be used for the treatment of tumor and for manufacturing an anti-tumor medicament. | 2010-12-02 |
20100303894 | POX VIRIDAE TREATMENT - A vaccine composition for combating | 2010-12-02 |
20100303895 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS - Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders. | 2010-12-02 |
20100303896 | 5BETA, 14BETA-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF RESTENOSIS AFTER ANGIOPLASTIC OR ENDOARTHERECTOMY AND DISEASES DUE TO ORGAN FIBROSIS - Compound of formula (I), wherein the symbol have the meaning reported in the text; for preparing a medicament for the prevention and/or treatment of obstructive vascular lesions following vascular surgery and for the prevention and/or treatment of diseases due to organ fibrosis. | 2010-12-02 |
20100303897 | NOVEL ADDL RECEPTOR POLYPEPTIDES, POLYNUCLEOTIDES AND HOST CELLS FOR RECOMBINANT PRODUCTION - This invention provides a novel receptor expressed on neuronal cells in a developmentally-specific manner. Accordingly, this invention provides the amino acid sequences of selected portions of the receptor and polynucleotides encoding these portions as well as antibodies that bind to the polypeptide portions of the receptor. Compositions and methods for using the compositions are also provided. | 2010-12-02 |